Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
1.4300 x 1 1.4800 x 40
Post-market by (Cboe BZX)
1.4700 +0.1000 (+7.30%) 04/23/25 [NASDAQ]
1.4300 x 1 1.4800 x 40
Post-market 1.4720 +0.0020 (+0.14%) 17:22 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.4000
Day High
1.5400
Open 1.4200
Previous Close 1.3700 1.3700
Volume 3,212,325 3,212,325
Avg Vol 6,724,341 6,724,341
Stochastic %K 49.97% 49.97%
Weighted Alpha -62.57 -62.57
5-Day Change -0.0700 (-4.55%) -0.0700 (-4.55%)
52-Week Range 1.1500 - 9.9700 1.1500 - 9.9700
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,513
  • Shares Outstanding, K 155,119
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,700 K
  • EBIT $ -114 M
  • EBITDA $ -107 M
  • 60-Month Beta 1.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 135.83% ( +4.79%)
  • Historical Volatility 167.73%
  • IV Percentile 60%
  • IV Rank 31.14%
  • IV High 273.17% on 12/09/24
  • IV Low 73.71% on 02/20/25
  • Put/Call Vol Ratio 0.34
  • Today's Volume 754
  • Volume Avg (30-Day) 2,305
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 64,310
  • Open Int (30-Day) 65,121

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +34.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +27.83%
on 04/08/25
Period Open: 3.3200
3.3600 -56.25%
on 03/24/25
-1.8500 (-55.72%)
since 03/21/25
3-Month
1.1500 +27.83%
on 04/08/25
Period Open: 4.5900
4.8500 -69.69%
on 01/31/25
-3.1200 (-67.97%)
since 01/23/25
52-Week
1.1500 +27.83%
on 04/08/25
Period Open: 3.9300
9.9700 -85.26%
on 05/31/24
-2.4600 (-62.60%)
since 04/23/24

Most Recent Stories

More News
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish

Fourth-quarter loss per share came in at $0.16, lower than the $0.24 in the corresponding period of 2023, and below the consensus estimate of $0.25, according to FinChat data.

HUMA : 1.4700 (+7.30%)
VTI : 263.44 (+1.70%)
IWM : 190.25 (+1.48%)
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

HUMA : 1.4700 (+7.30%)
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

HUMA : 1.4700 (+7.30%)
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

HUMA : 1.4700 (+7.30%)
Humacyte, Inc. Announces Proposed Public Offering of Common Stock

HUMA : 1.4700 (+7.30%)
Durable Goods, Home Sales in U.S. Due Next Week

U.S. Monday Economic Lookahead S&P flash U.S. services PMI (March) S&P flash ...

CNM : 50.43 (+1.49%)
HUMA : 1.4700 (+7.30%)
MKC : 76.60 (+1.14%)
BRZE : 28.34 (+1.47%)
DLTR : 83.43 (+1.55%)
TMC : 2.55 (+8.05%)
EPAC : 39.07 (+1.74%)
DIV.TO : 2.85 (+0.71%)
KBH : 53.47 (-0.35%)
LULU : 265.85 (+1.58%)
CKPT : 4.04 (unch)
KEI.TO : 9.56 (-2.05%)
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvessâ„¢ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

HUMA : 1.4700 (+7.30%)
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvessâ„¢ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

HUMA : 1.4700 (+7.30%)
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

HUMA : 1.4700 (+7.30%)
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvessâ„¢ and Other Bioengineered Tissues

HUMA : 1.4700 (+7.30%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 1.6800
2nd Resistance Point 1.6100
1st Resistance Point 1.5400
Last Price 1.4700
1st Support Level 1.4000
2nd Support Level 1.3300
3rd Support Level 1.2600

See More

52-Week High 9.9700
Fibonacci 61.8% 6.6008
Fibonacci 50% 5.5600
Fibonacci 38.2% 4.5192
Last Price 1.4700
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective